CSPC Pharmaceutical Group (1093) Price & Analysis

Compare

22 Followers

1093 Stock Chart & Stats

HK$7.52

HK$0.04(0.91%)

At close: Jan 09 4:00 PM EST

HK$7.52

HK$0.04(0.91%)

Day’s Range― - ―

52-Week RangeHK$4.27 - HK$11.63

Previous CloseN/A

Volume61.16M

Average Volume (3M)135.86M

Market Cap

HK$84.66B

Enterprise ValueHK$80.96B

Total Cash (Recent Filing)HK$10.63B

Total Debt (Recent Filing)HK$495.00M

Price to Earnings (P/E)20.4

Beta0.94

Next Earnings

Mar 25, 2026

EPS Estimate

0.14

Next Dividend Ex-DateN/A

Dividend Yield3.19%

Share Statistics

EPS (TTM)0.09

Shares Outstanding11,522,452,000

10 Day Avg. Volume105,139,995

30 Day Avg. Volume135,859,703

Financial Highlights & Ratios

PEG Ratio-0.53

Price to Book (P/B)1.63

Price to Sales (P/S)1.90

P/FCF Ratio30.23

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

HK$10.82

Price Target Upside43.83% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering18

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Cost ManagementThe selling expense ratio has significantly decreased, indicating improved cost management and potential for better profitability.

Earnings GrowthCSPC's BD deals are expected to be a key sustainable driver of earnings growth.

Out-licensing AgreementsCSPC has signed six out-licensing agreements across a diverse portfolio of assets, indicating a strong out-licensing potential that could drive sustainable income.

Bears Say

Revenue DeclineCore revenue, excluding business development income, has decreased by 19% year-over-year, reflecting challenges in sustaining sales growth.

CSPC Pharmaceutical Group News

CSPC Pharmaceutical Reshapes Top Management, Names Cai Lei as New CEO

CSPC Pharmaceutical Group ( ($HK:1093) ) has provided an update. CSPC Pharmaceutical Group has announced a leadership reshuffle...

15h ago

CSPC Pharmaceutical Updates Board and Committee Composition

CSPC Pharmaceutical Group ( ($HK:1093) ) has provided an announcement. CSPC Pharmaceutical Group Limited has disclosed an updated...

15h ago

CSPC Wins China Trial Green Light for Novel Oral Influenza Drug SYH2085

An update from CSPC Pharmaceutical Group ( ($HK:1093) ) is now available. CSPC Pharmaceutical Group has received approval...

15h ago

CSPC’s Secukinumab Biosimilar Hits Phase III Equivalence Target in Psoriasis

An update from CSPC Pharmaceutical Group ( ($HK:1093) ) is now available. CSPC Pharmaceutical Group has reported positive...

2d ago

CSPC Pharmaceutical Gains Approval for New Cancer Treatment Indication

CSPC Pharmaceutical Group ( ($HK:1093) ) just unveiled an announcement. CSPC Pharmaceutical Group has received marketing approval from...

8d ago

CSPC Innovation Seeks H Share Listing Amid Expansion Plans

CSPC Pharmaceutical Group ( ($HK:1093) ) has shared an announcement. CSPC Pharmaceutical Group announced that its subsidiary, CSPC...

9d ago

CSPC Pharmaceutical Gains U.S. FDA Approval for JMT206 Clinical Trials

The latest announcement is out from CSPC Pharmaceutical Group ( ($HK:1093) ). CSPC Pharmaceutical Group Limited has received...

10d ago

CSPC Pharmaceutical’s Semaglutide Injection Gains NMPA Acceptance

CSPC Pharmaceutical Group ( ($HK:1093) ) has provided an announcement. CSPC Pharmaceutical Group Limited announced that its second...

12d ago

CSPC’s Innovative Obesity Drug Receives U.S. Clinical Trial Approval

An update from CSPC Pharmaceutical Group ( ($HK:1093) ) is now available. CSPC Pharmaceutical Group Limited has announced...

15d ago

CSPC Pharmaceutical’s Antidepressant Drug Gains U.S. FDA Trial Approval

CSPC Pharmaceutical Group ( ($HK:1093) ) has provided an update. CSPC Pharmaceutical Group Limited has announced that its...

17d ago

1093 FAQ

What was CSPC Pharmaceutical Group Limited’s price range in the past 12 months?

CSPC Pharmaceutical Group Limited lowest stock price was HK$4.27 and its highest was HK$11.63 in the past 12 months.

What is CSPC Pharmaceutical Group Limited’s market cap?

CSPC Pharmaceutical Group Limited’s market cap is HK$84.66B.

When is CSPC Pharmaceutical Group Limited’s upcoming earnings report date?

CSPC Pharmaceutical Group Limited’s upcoming earnings report date is Mar 25, 2026 which is in 95 days.

How were CSPC Pharmaceutical Group Limited’s earnings last quarter?

CSPC Pharmaceutical Group Limited released its earnings results on Nov 20, 2025. The company reported HK$0.088 earnings per share for the quarter, missing the consensus estimate of HK$0.129 by -HK$0.041.

Is CSPC Pharmaceutical Group Limited overvalued?

According to Wall Street analysts CSPC Pharmaceutical Group Limited’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does CSPC Pharmaceutical Group Limited pay dividends?

CSPC Pharmaceutical Group Limited pays a Semiannually dividend of HK$0.14 which represents an annual dividend yield of 3.19%. See more information on CSPC Pharmaceutical Group Limited dividends here

What is CSPC Pharmaceutical Group Limited’s EPS estimate?

CSPC Pharmaceutical Group Limited’s EPS estimate is 0.14.

How many shares outstanding does CSPC Pharmaceutical Group Limited have?

CSPC Pharmaceutical Group Limited has 11,522,452,000 shares outstanding.

What happened to CSPC Pharmaceutical Group Limited’s price movement after its last earnings report?

CSPC Pharmaceutical Group Limited reported an EPS of HK$0.088 in its last earnings report, missing expectations of HK$0.129. Following the earnings report the stock price went up 1.982%.

Which hedge fund is a major shareholder of CSPC Pharmaceutical Group Limited?

Currently, no hedge funds are holding shares in HK:1093

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

CSPC Pharmaceutical Group Stock Smart Score

Outperform

Fundamentals

Return on Equity

11.30%

Trailing 12-Months

Asset Growth

-2.61%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

CSPC Pharmaceutical Group Limited

CSPC Pharmaceutical Group Limited, headquartered in Shijiazhuang, China, is a leading pharmaceutical enterprise specializing in the research, development, manufacturing, and marketing of a wide range of pharmaceutical products. The company operates across various sectors, including prescription drugs, over-the-counter products, and active pharmaceutical ingredients (APIs). Its core products encompass a diverse portfolio of therapeutic areas such as oncology, cardiovascular diseases, and anti-infectives, positioning CSPC as a significant player in both domestic and international pharmaceutical markets.

CSPC Pharmaceutical Group (1093) Earnings & Revenues

Historic Earnings Reports

1093 Stock 12 Month Forecast

Average Price Target

HK$10.82

▲(43.83% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"HK$3","18":"HK$18","6.75":"HK$6.75","10.5":"HK$10.5","14.25":"HK$14.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":17.39999999038824,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">HK$17.40</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10.815942226,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">HK$10.82</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6.59999999635416,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">HK$6.60</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3,6.75,10.5,14.25,18],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.85,8.584615383876018,9.319230767752035,10.053846151628054,10.788461535504073,11.523076919380092,12.25769230325611,12.992307687132127,13.726923071008146,14.461538454884165,15.196153838760182,15.9307692226362,16.66538460651222,{"y":17.39999999038824,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.85,8.078149402,8.306298803999999,8.534448206,8.762597608,8.99074701,9.218896412,9.447045814,9.675195216,9.903344618,10.13149402,10.359643422000001,10.587792824000001,{"y":10.815942226,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.85,7.753846153565704,7.657692307131409,7.561538460697113,7.465384614262818,7.3692307678285225,7.273076921394227,7.176923074959932,7.080769228525637,6.9846153820913415,6.888461535657045,6.79230768922275,6.696153842788455,{"y":6.59999999635416,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":4.939,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.647,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.355,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.579,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.328,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.96,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.496,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.583,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.74,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.824,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.228,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.65,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.85,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >